KNOWLEDGE / Publication / POST
August 7, 2019

Scientific Poster Publication made on March 2018 at the American Society for Clinical Pharmacology and Therapeutics, Orlando (USA).

Often, the primary endpoint of RCTs is defined as a change from baseline of a continuous outcome. In
such cases, regulators recommend including the outcome’s baseline value as a covariate in the
statistical analysis. Regression to the mean can explain the benefits of this procedure.

We modeled the regression to the mean effect in this context. We found that the correlation between
baseline and endpoint is a function of the outcome’s signal to noise ratio (SNR). The SNR is the ratio of
the inter-patient and the intra-patient variabilities. We observed that lower is the SNR, higher is the
correlation and more efficient is the covariate correction.

To increase this correction, we proposed to combine several baseline measurements in a covariate
minimizing the SNR with respect to the primary endpoint. This methodology was tested on placebo
patients of two studies in Neuropathic Pain. The continuous outcomes were the weekly mean of the
daily average pain score (APS), the brief pain inventory (BPI), and the worst pain score (WPS). The
primary endpoint was the change from baseline of the APS.

As covariate, the baseline value of the APS outcome was able to explain 10.8% of the primary endpoint
variance (Adj R-squared with p-value=0.00108). As proposed, we combined the baseline values of the
pain outcomes into a single covariate having a low SNR. This new covariate increased the explained
variance of the primary endpoint up to 28.5% (Adj R-squared with p-value<5e-08).

The correction for the baseline value of a continuous outcome is a standard procedure recommended
by regulatory agencies. Using theoretical analysis of this effect, we improved this procedure and tested it successfully in two pain studies with neuropathic patients.

Scientific Poster
Samuel Branders, PhD; Guillaume Bernard, PhD; Alvaro Pereira, PhD
March 1, 2018
American Society for Clinical Pharmacology and Therapeutics


Related content


Do Environmental Parameters Influence The Prediction Of The Placebo Response?

This proof-of-concept study on peripheral neuropathic pain patients investigates the potential influence of the investigator on the placebo…

Read More

Bayesian Modeling Of The Placebo Response In Neuropathic Pain

In analgesia randomized clinical trials (RCTs), the magnitude and the variability of the placebo response have a negative…

Type: Scientific Poster
Authors: Samuel Branders, PhD; Alvaro Pereira, PhD; Frederic Clermont, PhD; Chantal Gossuin; Dominique Demolle, PhD
Conference: Promoting Statistical Insight Conference
Read More

Leveraging Historical Data For High-dimensional Covariate-adaptive Randomization, A Machine Learning Approach.

There is a continuous growth in data collected in clinical trials. Many of those patient's characteristics are potential…

Type: Scientific Presentation
Authors: Samuel Branders, PhD; Guillaume Bernard, PhD; Alvaro Pereira, PhD
Conference: Promoting Statistical Insight Conference
Read More

The next frontier in clinical research & patient management

We’re proud to be leading the charge into the next era of drug development.
Cognivia helps clinical trials reduce data variability, empower decision-making, and accelerate the launch of new therapies.
Tell us about your clinical trial below and we’ll be in touch.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.